West Pharmaceutical Services (WST) Net Cash Flow (2009 - 2026)

West Pharmaceutical Services has disclosed Net Cash Flow across 18 years of filings, most recently posting -$261.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$261.5 million, down 194.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.2 million (up 157.5% YoY), and the FY2025 annual result was $283.8 million, up 181.58% from the prior year.
• Net Cash Flow came in at -$261.5 million for Q1 2026 at West Pharmaceutical Services, down from $163.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $163.3 million in Q4 2025 to a low of -$261.5 million in Q1 2026.
• The 5-year median for Net Cash Flow is $16.4 million (2024), against an average of -$13.8 million.
• Across the five-year window, Net Cash Flow sank 1522.67% in 2024 and soared 895.73% in 2025, its largest moves.
• West Pharmaceutical Services' Net Cash Flow stood at $126.5 million in 2022, then plunged by 146.8% to -$59.2 million in 2023, then soared by 127.7% to $16.4 million in 2024, then jumped by 895.73% to $163.3 million in 2025, then slumped by 260.13% to -$261.5 million in 2026.
• The last three Net Cash Flow figures came in at -$261.5 million (Q1 2026), $163.3 million (Q4 2025), and $122.4 million (Q3 2025), per Business Quant data.